Pharma Mar SA said a combination of Zepsyre and chemotherapy reduced the tumor size of patients with relapsed small cell lung cancer in a phase 1/2 trial.
The Zepsyre phase 1/2 trials, conducted in 27 patients, showed that a combination of the drug and doxorubicin is better than topotecan alone. The combination had a progression-free survival of 5.3 months compared to topotecan's historical data of 3.1 to 3.5 months progression-free survival.
Further, the combination also demonstrated a 37% objective response rate versus the topotecan rates of between 17% and 24%.
The results of the trial were presented by PharmaMar at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer held in Japan.